Afexa Life Sciences Inc.
TSX VENTURE : CVQ

Afexa Life Sciences Inc.

September 27, 2005 09:00 ET

720 Seniors in 3 Canadian Cities to Join National Trial of COLD-fX® to Protect them from Influenza & Cold Viruses

EDMONTON, ALBERTA--(CCNMatthews - Sept. 27, 2005) -

International & National Experts in Influenza, Infectious Diseases and Public Health to Collaborate on Study

CV Technologies Inc. (CVT) (TSX VENTURE:CVQ) today announced that 720 healthy seniors in Edmonton, Toronto and Vancouver will be involved in a national trial designed to protect them from influenza and cold viral infections. Edmonton's Medical Officer of Health will head the national study. He will collaborate with internationally recognized influenza expert and newly appointed Head of Geriatrics at University of British Columbia and Providence Health Care, Dr. Janet McElhaney and two other Vancouver researchers, as well as infectious disease expert Dr. Andrew Simor, Head of Microbiology at Sunnybrook and Women's College Health Sciences Centre in Toronto. A diverse population of 720 generally healthy seniors will participate in the study involving COLD-fX®.

The trial is designed to investigate the effectiveness of COLD-fX® in the prevention of respiratory infections in community-dwelling seniors who have been vaccinated against influenza. Participants will take either 400 mg COLD-fX®/day (standard dose), 800 mg COLD-fX®/day (high dose), or Placebo, for a period of 6 months. They will be asked to report a respiratory infection and record their symptoms. Throat swab samples will be taken from those reporting an infection and they will be analyzed specifically for influenza A, influenza B, parainfluenza 1, 2, and 3, and respiratory syncytial virus (RSV).

Dr. Predy says, "We are pleased to launch this trial since our previous prevention trial with COLD-fX® in a younger general population demonstrated some promising results to warrant a larger, longer and multi-dosage study in order to find out the optimal prevention regime against influenza and cold viral infections in community seniors."

Dr. Simor says, "We have been interested in the previous laboratory and clinical evidence on COLD-fX®. We are pleased to be able to participate in this trial in Toronto since the objective of the study represents searching for a whole new direction in preventing and managing influenza and cold viral infections through immune modulation."

Dr. Janet McElhaney says, "There is a great need to find ways to improve protection against the flu and other respiratory infections in seniors. Our two previous FDA regulated studies conducted in the U.S demonstrated an 89% relative risk reduction in the incidence of lab-confirmed clinical influenza and RSV infection in nursing home seniors. More importantly, the previous studies demonstrated that COLD-fX® had an excellent safety profile causing minimal adverse events. The current study is much larger and from a broader population of seniors from three diverse areas of the country and this should help us further understand the potential of COLD-fX® for this most vulnerable group."

CV Technologies Inc. CEO and Chief Scientific Officer, Dr. Jacqueline Shan says, "The flu vaccine, although currently the best option for preventing influenza infection, is not as effective in seniors. There is no vaccine available against cold viruses and currently none available for possible new strains of influenza. Previous clinical and immunological studies suggested that COLD-fX® offers a broader spectrum of anti-viral properties through enhancing immune cell's natural viral fighting mechanism. Therefore, COLD-fX® may be useful as a complementary or alterative therapy to the flu vaccine."

Dr. Shan adds, "The launch of this trial further demonstrates our continued commitment to evidence-based natural health product research. We are particularly pleased that some of the leading experts in infectious diseases and geriatric medicine in the country are collaborating and conducting this study. This will also certainly help to raise the overall standard of NHP research and development in the country."

Apart from COLD-fX®, there is no known therapy for both prevention and treatment of infections that is designed to naturally enhance the immune system to fight viral respiratory infections. There is no vaccine available for any of the more than 200 strains of cold viruses, and antiviral medications are not effective. For influenza, vaccination is the cornerstone of prevention, but the need for added protection against influenza illness in persons age 65 and older is well recognized. Because influenza viruses are capable of mutating rapidly, they may change from those contained in the vaccine and reduce the vaccine's protective effects. The influenza virus can also develop resistance to antiviral medication.

This is the first multi-dose, multi-centre trial (largest) conducted on COLD-fX® and the first to measure the potential effect of a larger dose. It has been authorized by the Natural Health Products Directorate of Health Canada, which just recently launched this year's flu surveillance program.

Experts estimate that seven hundred North Americans die each week from flu-related complications and the majority of those people are seniors. In fact it is the fourth leading cause of death for adults over 65.

Capital Health is initiating its recruiting program immediately in Edmonton and interested seniors may phone 908-2616 or 908-3515 for further information. Recruitment at Vancouver and Toronto is planned in conjunction with local vaccination clinics.

ABOUT CV TECHNOLOGIES INC.

CV Technologies was founded in 1992. It aims to become a global leader in the development and commercialization of evidence based, natural medicines for disease prevention and health maintenance. CVT's lead product - COLD-fX®, - the top selling cold remedy in Canada according to ACNielsen, strengthens the immune system and is widely used as a leading anti-cold, anti-flu, non-prescription treatment. COLD-fX's unique, patented, mechanism of action was developed and standardized according to the Company's ChemBioPrint (CBP™) technology. The CBP™ process precisely identifies the chemical profile and biological activity of multi-active components in natural compounds. The CBP™ process provides a manufacturing protocol that ensures each batch of compound delivers verifiable and provable health benefits.

This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.

Contact Information